FDA Orange Book
Generic for Evoclin
Evoclin contains clindamycin. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Evoclin is clindamycin. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AT.
Run it in Rivvi
Map Evoclin and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Evoclin products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| aerosol, foam, topical | 1% | Discontinued | None | 3 | AT |
NDA 050801, held by QUAGEN PHARMACEUTICALS LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic clindamycin
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| PADAGIS ISRAEL PHARMACEUTICALS LTD | 090785 | AT (A-rated, therapeutically equivalent) | March 31, 2010 | 1% |
| TARO PHARMACEUTICAL INDUSTRIES LTD | 210004 | AT (A-rated, therapeutically equivalent) | March 11, 2020 | 1% |
| GLENMARK PHARMACEUTICALS LTD | 210778 | AT (A-rated, therapeutically equivalent) | September 20, 2021 | 1% |
Questions
Is there a generic for Evoclin?
Yes. The generic name for Evoclin is clindamycin. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AT.
What is the generic name for Evoclin?
The active ingredient in Evoclin is clindamycin, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.